---
title: 'The Niche Episode 068 – Eli Lilly + ProQR, Sanofi + Kadmon, Lycia, BlueBird + 2seventy, Mammoth'
type: 'episode'
url: 'https://doc.social/episodes/the-niche-episode-068-eli-lilly-proqr-sanofi-kadmon-lycia-bluebird-2seventy-mammoth'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2021-09-15'
audio: 'unavailable — the host retired the file'
---

# The Niche Episode 068 – Eli Lilly + ProQR, Sanofi + Kadmon, Lycia, BlueBird + 2seventy, Mammoth

$1.5B deal, $1.9B merger, protein degraders get backing, an old bird has new tricks, and another billion-dollar valuation for CRISPRFind out more athttps://thenichepod.comStory Referenceshttps://tinyurl.com/Niche-068-1 https://tinyurl.com/N…

## Summary

$1.5B deal, $1.9B merger, protein degraders get backing, an old bird has new tricks, and another billion-dollar valuation for CRISPR

**Find out more at
**[https://thenichepod.com](https://thenichepod.com)

**Story References
**[https://tinyurl.com/Niche-068-1](https://tinyurl.com/Niche-068-1)
 [https://tinyurl.com/Niche-068-2](https://tinyurl.com/Niche-068-2)
[https://tinyurl.com/Niche-068-3](https://tinyurl.com/Niche-068-3)
[https://tinyurl.com/Niche-068-4](https://tinyurl.com/Niche-068-4)
[https://tinyurl.com/Niche-068-5](https://tinyurl.com/Niche-068-5)
[https://tinyurl.com/Niche-068-6](https://tinyurl.com/Niche-068-6)

**Music by Luke Goodson
**[https://www.soundcloud.com/lukegoodson](https://www.soundcloud.com/lukegoodson)

The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.